Iterum Therapeutics to Present Data at IDWeek 2024

Rhea-AI Summary

Iterum Therapeutics (Nasdaq: ITRM) announced its participation in IDWeek 2024, presenting three posters at the conference in Los Angeles from October 16-19, 2024. The presentations focus on the company's oral antibiotic sulopenem and its applications in treating uncomplicated urinary tract infections (uUTI) and inhalational anthrax.

The posters include results from the REASSURE trial on oral sulopenem/probenecid for uUTI, an analysis of asymptomatic bacteriuria in uUTI patients from the same trial, and the efficacy of sulopenem in a rabbit model of inhalational anthrax. All presentations will be given by Dr. Steven I. Aronin on October 18, with specific times and locations provided.

Iterum Therapeutics will make these posters available on their website's 'Publications: Posters & Presentations' page after the conference concludes.

DUBLIN and CHICAGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that three posters will be presented at the Infectious Disease Society of America’s IDWeek 2024 conference taking place in Los Angeles, CA from October 16-19, 2024.

Data to be presented at IDWeek 2024 include:

Presentation Title: Oral Sulopenem/probenecid for Uncomplicated Urinary Tract Infections (uUTI): Results from the REASSURE Trial
Poster #:   1107
Presenter: Steven I. Aronin, MD
Time/Location:   Friday, October 18, 12:15 p.m. - 1:30 p.m.

Presentation Title: Asymptomatic Bacteriuria Not a Predictor of Clinical Failure in Uncomplicated Urinary Tract Infections (uUTI): A Prospective Analysis of Women Treated for uUTI from the REASSURE Trial
Poster #:   1574
Presenter: Steven I. Aronin, MD
Time/Location:   Rapid Fire Poster Presentation, Friday October 18, 12:35 p.m. - 12:40 p.m., Halls JK – Arena 4.

Presentation Title: Sulopenem is Efficacious in a Rabbit Model of Inhalational Anthrax
Poster #: 1106
Presenter: Steven I. Aronin, MD
Time/Location: Friday, October 18, 12:15 p.m. - 1:30 p.m.

These Posters will be made available on the Company’s website on the “Publications: Posters & Presentations” page under the “Our Science” tab once the conference ends.

About Iterum Therapeutics plc

Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has submitted an NDA for oral sulopenem for the treatment of uncomplicated urinary tract infections in adult women, which has been accepted for review by the U.S. Food and Drug Administration and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit http://iterumtx.com.

Investor Contact:
Judy Matthews
Chief Financial Officer
312-778-6073
IR@iterumtx.com 

FAQ

What data will Iterum Therapeutics (ITRM) present at IDWeek 2024?

Iterum Therapeutics will present three posters at IDWeek 2024, focusing on sulopenem for uncomplicated urinary tract infections (uUTI) and inhalational anthrax. The presentations include results from the REASSURE trial and a rabbit model study.

When and where will Iterum Therapeutics (ITRM) present at IDWeek 2024?

Iterum Therapeutics will present at IDWeek 2024 in Los Angeles, CA from October 16-19, 2024. The specific presentations are scheduled for October 18, 2024, at various times between 12:15 p.m. and 1:30 p.m.

Who will present Iterum Therapeutics' (ITRM) data at IDWeek 2024?

Dr. Steven I. Aronin will present all three posters for Iterum Therapeutics at IDWeek 2024.

What is the REASSURE trial mentioned in Iterum Therapeutics' (ITRM) IDWeek 2024 presentations?

The REASSURE trial is a study conducted by Iterum Therapeutics on oral sulopenem/probenecid for treating uncomplicated urinary tract infections (uUTI). Results from this trial will be presented at IDWeek 2024.

How can I access Iterum Therapeutics' (ITRM) IDWeek 2024 posters after the conference?

Iterum Therapeutics will make the posters available on their website's 'Publications: Posters & Presentations' page under the 'Our Science' tab after the IDWeek 2024 conference ends.